Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY 2,395.00
+45.00 (1.91%)
Mar 24, 2026, 3:30 PM JST
Kyowa Kirin Employees
Kyowa Kirin had 5,669 employees as of December 31, 2024. The number of employees decreased by 305 or -5.11% compared to the previous year.
Employees
5,669
Change (1Y)
-305
Growth (1Y)
-5.11%
Revenue / Employee
87.64M JPY
Profits / Employee
11.83M JPY
Market Cap
1.25T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 5,669 | -305 | -5.11% |
| Dec 31, 2023 | 5,974 | 222 | 3.86% |
| Dec 31, 2021 | 5,752 | 329 | 6.07% |
| Dec 31, 2020 | 5,423 | 156 | 2.96% |
| Dec 31, 2019 | 5,267 | -1,975 | -27.27% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Otsuka Holdings | 37,758 |
| Daiichi Sankyo Company | 19,765 |
| Astellas Pharma | 13,643 |
| Chugai Pharmaceutical | 7,872 |
| Ono Pharmaceutical | 4,287 |
| Santen Pharmaceutical | 3,849 |
| JCR Pharmaceuticals | 987 |
| Perseus Proteomics | 32 |
Kyowa Kirin News
- 21 days ago - Amgen (AMGN) and Kyowa Kirin Halt Clinical Trials for Rocatinlimab Over Safety Concerns - GuruFocus
- 21 days ago - Kyowa Kirin stops development of skin condition treatment - Reuters
- 7 weeks ago - Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends - Benzinga
- 3 months ago - Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman - Business Wire
- 4 months ago - Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting - GlobeNewsWire
- 5 months ago - Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region - Business Wire
- 5 months ago - Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases - GlobeNewsWire
- 5 months ago - Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan - GlobeNewsWire